TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+12.54%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.14B
AUM Growth
+$2.14B
(+5%)
Cap. Flow
-$122M
Cap. Flow
% of AUM
-5.71%
Top 10 Holdings %
Top 10 Hldgs %
48.86%
Holding
101
New
8
Increased
17
Reduced
23
Closed
9
Top Buys
| 1 |
Biogen
BIIB
|
$47.7M |
| 2 |
SHPG
Shire pic
SHPG
|
$33.6M |
| 3 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
$20.5M |
| 4 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
$13.8M |
| 5 |
Ventas
VTR
|
$11.2M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$38.6M |
| 2 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
$32.8M |
| 3 |
Illumina
ILMN
|
$23.2M |
| 4 |
Amgen
AMGN
|
$20.7M |
| 5 |
IPXL
Impax Laboratories, Inc.
IPXL
|
$20.5M |
Sector Composition
| 1 | Healthcare | 85.41% |
| 2 | Real Estate | 4.11% |
| 3 | Financials | 1.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $223M | 10.45% | 1,994,834 -41,600 | -2% | -$4.65M |
|
|
2
Gilead Sciences
GILD
$140B
| $196M | 9.18% | 2,080,731 -409,800 | -16% | -$38.6M |
|
|
3
Biogen
BIIB
$19.4B
| $111M | 5.2% | 327,283 +140,500 | +75% | +$47.7M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $88.3M | 4.13% | 477,105 +25,200 | +6% | +$4.66M |
|
5
Vertex Pharmaceuticals
VRTX
$100B
| $83.4M | 3.9% | 701,944 | – | – |
|
6
Regeneron Pharmaceuticals
REGN
$61.5B
| $81.4M | 3.81% | 198,366 +11,200 | +6% | +$4.59M |
|
|
AGN
7
DELISTED
Allergan plc
AGN
| $71.5M | 3.35% | 277,631 | – | – |
|
8
Incyte
INCY
$16.5B
| $68.5M | 3.2% | 936,461 -205,500 | -18% | -$15M |
|
|
9
Amgen
AMGN
$155B
| $60.6M | 2.84% | 380,279 -129,763 | -25% | -$20.7M |
|
|
SHPG
10
DELISTED
Shire pic
SHPG
| $59.8M | 2.8% | 281,522 +158,200 | +128% | +$33.6M |
|
11
Viatris
VTRS
$12.3B
| $56.9M | 2.67% | 1,010,105 | – | – |
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $51.5M | 2.41% | 570,027 -140,500 | -20% | -$12.7M |
|
13
Pfizer
PFE
$141B
| $51M | 2.39% | 1,638,241 -264,000 | -14% | -$8.22M |
|
|
AGN
14
DELISTED
ALLERGAN INC
AGN
| $48.5M | 2.27% | 228,227 | – | – |
|
15
AbbVie
ABBV
$372B
| $38.9M | 1.82% | 594,219 +113,000 | +23% | +$7.39M |
|
16
Johnson & Johnson
JNJ
$427B
| $34.2M | 1.6% | 327,212 | – | – |
|
17
Jazz Pharmaceuticals
JAZZ
$7.75B
| $33M | 1.54% | 201,341 +28,100 | +16% | +$4.6M |
|
18
Bristol-Myers Squibb
BMY
$96B
| $31.6M | 1.48% | 535,240 | – | – |
|
|
AKRX
19
DELISTED
Akorn, Inc.
AKRX
| $30.8M | 1.44% | 849,482 +150,100 | +21% | +$5.43M |
|
|
AET
20
DELISTED
Aetna Inc
AET
| $29.5M | 1.38% | 331,931 -57,100 | -15% | -$5.07M |
|
21
Alkermes
ALKS
$4.78B
| $25.6M | 1.2% | 436,970 | – | – |
|
22
Teva Pharmaceuticals
TEVA
$21.1B
| $24.4M | 1.14% | 423,594 -228,600 | -35% | -$13.1M |
|
|
CTRX
23
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $22.4M | 1.05% | 433,600 | – | – |
|
|
NPSP
24
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $22.4M | 1.05% | 625,900 +387,000 | +162% | +$13.8M |
|
25
Neurocrine Biosciences
NBIX
$13.8B
| $22.3M | 1.05% | 1,000,350 -281,600 | -22% | -$6.29M |
|